User login
Key clinical point: Nanoparticle albumin-bound paclitaxel (nab-paclitaxel) was associated with a higher incidence of chemotherapy-induced peripheral neuropathy (CIPN) than docetaxel or paclitaxel in women with invasive breast cancer (BC).
Major finding: The risk for patient-reported CIPN was lower in the paclitaxel (hazard ratio [HR] 0.59; P = .008) and docetaxel (HR 0.65; P = .02) groups compared with the nab-paclitaxel group, with lesser sensory discomfort being reported by patients receiving paclitaxel (HR 0.44) or docetaxel (HR 0.52; both P < .001) vs nab-paclitaxel.
Study details: Findings are from a prospective cohort study including 1234 patients with invasive BC who received taxane-containing chemotherapy, of which 23.9%, 41.7%, and 34.4% of patients received nab-paclitaxel, paclitaxel, and docetaxel, respectively.
Disclosures: This study was supported by the Chinese Academy of Medical Sciences Innovation Fund for Medical Sciences. Dr. Xu declared receiving personal fees from several sources.
Source: Mo H et al. Association of taxane type with patient-reported chemotherapy-induced peripheral neuropathy among patients with breast cancer. JAMA Netw Open. 2022;5(11):e2239788 (Nov 2). Doi: 10.1001/jamanetworkopen.2022.39788
Key clinical point: Nanoparticle albumin-bound paclitaxel (nab-paclitaxel) was associated with a higher incidence of chemotherapy-induced peripheral neuropathy (CIPN) than docetaxel or paclitaxel in women with invasive breast cancer (BC).
Major finding: The risk for patient-reported CIPN was lower in the paclitaxel (hazard ratio [HR] 0.59; P = .008) and docetaxel (HR 0.65; P = .02) groups compared with the nab-paclitaxel group, with lesser sensory discomfort being reported by patients receiving paclitaxel (HR 0.44) or docetaxel (HR 0.52; both P < .001) vs nab-paclitaxel.
Study details: Findings are from a prospective cohort study including 1234 patients with invasive BC who received taxane-containing chemotherapy, of which 23.9%, 41.7%, and 34.4% of patients received nab-paclitaxel, paclitaxel, and docetaxel, respectively.
Disclosures: This study was supported by the Chinese Academy of Medical Sciences Innovation Fund for Medical Sciences. Dr. Xu declared receiving personal fees from several sources.
Source: Mo H et al. Association of taxane type with patient-reported chemotherapy-induced peripheral neuropathy among patients with breast cancer. JAMA Netw Open. 2022;5(11):e2239788 (Nov 2). Doi: 10.1001/jamanetworkopen.2022.39788
Key clinical point: Nanoparticle albumin-bound paclitaxel (nab-paclitaxel) was associated with a higher incidence of chemotherapy-induced peripheral neuropathy (CIPN) than docetaxel or paclitaxel in women with invasive breast cancer (BC).
Major finding: The risk for patient-reported CIPN was lower in the paclitaxel (hazard ratio [HR] 0.59; P = .008) and docetaxel (HR 0.65; P = .02) groups compared with the nab-paclitaxel group, with lesser sensory discomfort being reported by patients receiving paclitaxel (HR 0.44) or docetaxel (HR 0.52; both P < .001) vs nab-paclitaxel.
Study details: Findings are from a prospective cohort study including 1234 patients with invasive BC who received taxane-containing chemotherapy, of which 23.9%, 41.7%, and 34.4% of patients received nab-paclitaxel, paclitaxel, and docetaxel, respectively.
Disclosures: This study was supported by the Chinese Academy of Medical Sciences Innovation Fund for Medical Sciences. Dr. Xu declared receiving personal fees from several sources.
Source: Mo H et al. Association of taxane type with patient-reported chemotherapy-induced peripheral neuropathy among patients with breast cancer. JAMA Netw Open. 2022;5(11):e2239788 (Nov 2). Doi: 10.1001/jamanetworkopen.2022.39788